phrykt

Hemab Therapeutics Holdings, Inc. (COAG): who owns it and who trades it

As of Nov 16, 2026, COAG insiders reported 16 purchases worth $55.5M in the last 12 months. The largest buyer was Rajeev M. Shah (Director), with $52.2M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Hemab Therapeutics Holdings

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns COAG

56 funds and institutions reported COAG shares worth $1.3B at the end of Q2 2026, about 78% of the company. The largest holder is Ra Capital Management, L.P. with 16.7%.

Funds and institutions (13F) 78%Everyone else 22%

10 largest owners, by share of the company

Ra Capital Management, L.P.16.7%
Novo Holdings A/s9.0%
FMR LLC (Fidelity)7.9%
Capital International Investors7.7%
Deep Track Capital, LP7.7%
Siren, L.L.C.4.5%
Avoro Capital Advisors LLC4.1%
Bain Capital Life Sciences Investors, LLC3.5%
JPMorgan Chase & Co2.5%
Vanguard Capital Management LLC1.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Ra Capital Management, L.P.7.81M16.72%$287M–
Novo Holdings A/s4.18M8.95%$154M–
FMR LLC (Fidelity)3.70M7.92%$136M–
Capital International Investors3.60M7.72%$132M–
Deep Track Capital, LP3.60M7.71%$132M–
Siren, L.L.C.2.09M4.47%$76.6M–
Avoro Capital Advisors LLC1.93M4.12%$70.7M–
Bain Capital Life Sciences Investors, LLC1.65M3.53%$60.6M–
JPMorgan Chase & Co1.15M2.47%$42.3M–
Vanguard Capital Management LLC780,7581.67%$28.7M–
T. Rowe Price Associates746,0401.60%$27.4M–
Driehaus Capital Management LLC715,7911.53%$26.3M–
Rock Springs Capital Management LP575,4321.23%$21.1M–
Bellevue Group AG550,0001.18%$20.2M–
Citadel Advisors LLC523,4501.12%$19.2M–
BlackRock, Inc.283,8330.61%$10.4M–
Deerfield Management Company, L.P.275,0000.59%$10.1M–
ExodusPoint Capital Management, LP218,2870.47%$8M–
Geode Capital Management, LLC211,7980.45%$7.8M–
Braidwell LP160,0000.34%$5.9M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, COAG insiders reported $55.5M of open-market purchases and $0 of sales.

Purchases, 12 months
$55.5M
16 trades, 4 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Jun 16, 2026
Filed Jun 17, 2026

Purchases and sales by month

$53.8M$53.8MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jun 16, 2026Ra Capital Management, L.P. +310% ownerPurchase61,523$24.98$1.5MForm 4
Jun 15, 2026Ra Capital Management, L.P. +310% ownerPurchase6,146$24.89$153KForm 4
May 20, 2026Ra Capital Management, L.P. +310% ownerPurchase996$24.94$24.8KForm 4
May 19, 2026Ra Capital Management, L.P. +310% ownerPurchase3,802$24.97$94.9KForm 4
May 12, 2026Peter Kolchinsky +310% ownerPurchase6,387$24.90$159KForm 4
May 11, 2026RA Capital Healthcare Fund LP +310% ownerPurchase25,720$25.00$643KForm 4
May 11, 2026RA Capital Healthcare Fund LP +310% ownerPurchase14,149$24.47$346KForm 4
May 8, 2026RA Capital Healthcare Fund LP +310% ownerPurchase1,483$24.98$37KForm 4
May 7, 2026RA Capital Healthcare Fund LP +310% ownerPurchase1,985$24.95$49.5KForm 4
May 7, 2026RA Capital Healthcare Fund LP +310% ownerPurchase7,921$24.34$193KForm 4
May 6, 2026Rajeev M. Shah +5DirectorPurchase53,407$24.83$1.3MForm 4
May 6, 2026Rajeev M. Shah +5DirectorPurchase14,611$23.77$347KForm 4
May 5, 2026Rajeev M. Shah +5DirectorPurchase10,268$25.00$257KForm 4
May 5, 2026Rajeev M. Shah +5DirectorPurchase87,143$24.59$2.1MForm 4
May 4, 2026Rajeev M. Shah +5DirectorPurchase133,750$18.00$2.4MForm 4
May 4, 2026Rajeev M. Shah +5DirectorPurchase2.54M$18.00$45.7MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Rajeev M. ShahDirector, 10% owner$52.2M–May 6, 2026
Ra Capital Management, L.P.10% owner$1.8M–Jun 16, 2026
RA Capital Healthcare Fund LP10% owner$1.3M–May 11, 2026
Peter Kolchinsky10% owner$159K–May 12, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

COAG short interest

Moderate short interest. 7.1% of COAG shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 336%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.31M COAG shares were sold short, 7.1% of the shares outstanding, up 4.6% from the report before. At the average daily volume of 451,955 shares, buying them all back would take about 7.3 trading days (days to cover).

Shares short, % of all shares

7.07%May 15Oct 308.10%

Days to cover

7.3May 15Oct 308.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.31M7.07%+5%451,9557.3
Oct 15, 20263.16M6.77%-7%404,7907.8
Sep 30, 20263.39M7.26%+28%811,2054.2
Sep 15, 20262.64M5.65%+25%350,1127.5
Aug 31, 20262.11M4.51%+4%349,4806.0
Aug 14, 20262.03M4.35%-0%330,0666.2
Jul 31, 20262.04M4.36%+23%479,2114.2
Jul 15, 20261.66M3.55%-3%311,2245.3
Jun 30, 20261.71M3.67%+27%423,7864.0
Jun 15, 20261.35M2.90%+32%179,4417.5
May 29, 20261.03M2.20%+35%158,0836.5
May 15, 2026758,6971.62%–622,6221.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Hemab Therapeutics Holdings company events

Hemab Therapeutics Holdings filed 6 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Sep 24, 2026LeadershipUpon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors of Hemab Therapeutics Holdings, Inc., the Board elected Keli Walbert to serve as a member of the Board, effective immediately. Filing
  3. Aug 11, 2026ResultsReleased financial results. Filing
  4. May 21, 2026ResultsReleased financial results. Filing
  5. May 11, 2026LeadershipLaura Tadvalkar, Ph.D., notified Hemab Therapeutics Holdings, Inc. of her decision to resign as a member of the Company’s board of directors, effective immediately. Filing
  6. May 4, 2026AnnouncementThe Company completed its IPO of 19,262,500 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,512,500 additional shares of common stock, at a public offering price of $18.00 per share. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Famous investors that hold COAG

4 of the 50 well-known investors we track reported holding COAG in their latest 13F filing. The largest position is Ken Griffin's, worth $2.8M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202690,412$2.8M0.0%-83%
Jim Simons · Renaissance TechnologiesQ3 202667,542$2.1M0.0%New
Israel Englander · Millennium ManagementQ3 202611,695$361K0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 20267,458$230K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named COAG in the last 120 days.

FiledHolderFormStake
Nov 6, 2026FMR LLC13G/A10.4%
Nov 6, 2026FMR LLC13G/A10.4%

Questions about Hemab Therapeutics Holdings, Inc. (COAG) stock

Who owns the most COAG stock?

The largest reported owner of Hemab Therapeutics Holdings, Inc. (COAG) is Ra Capital Management, L.P., with 16.7% of the company. In total, 56 funds and institutions reported holding COAG at the end of Q2 2026, together about 78% of the shares. See the largest owners.

Are COAG insiders buying or selling?

In the last 12 months, COAG insiders reported 16 open-market purchases worth $55.5M and no sales. The latest trade was on Jun 16, 2026. See every trade.

What is the short interest in COAG?

As of Oct 30, 2026, 3.31M COAG shares were sold short, 7.1% of the shares outstanding, up 4.6% from the report before. At the average daily volume of 451,955 shares, buying them all back would take about 7.3 trading days (days to cover). See the history.

Which famous investors hold COAG?

4 of the 50 well-known investors we track reported COAG in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $2.8M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.